Search
Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB22670ApprovedIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB22672ApprovedIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Austria/1359417/2021 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB16923ApprovedIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB18750ApprovedIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/District of Columbia/27/2023 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB22669ApprovedIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB22671ApprovedIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Perth/722/2024 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB31654ApprovedIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
PI-0824
go.drugbank.com/drugs/DB05516InvestigationalIt is hoped that use of PI-0824 will reduce or potentially eliminate the need for high dose steroids and drugs that suppress the immune system. … Currently, most doctors who treat patients with PV will prescribe high-dose steroids and drugs that suppress the immune system in an effort to decrease the production of these antibodies.
Influenza A virus A/West Virginia/30/2022 (H1N1) Recombinant Hemagglutinin Antigen
go.drugbank.com/drugs/DB17995ApprovedWithdrawnIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Georgia/12/2022 CVR-167 (H1N1) Antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB17996ApprovedIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.